Antitussive activity of iodo-resiniferatoxin in guinea pigs. Issue 9 (27th August 2004)

• Record Type: Journal Article
• Authors: Trevisani, M; Milan, A; Gatti, R; Zanasi, A; Harrison, S; Fontana, G; Morice, A H; Geppetti, P
• Is Part Of: Thorax. Volume 59:Issue 9(2004)
• Page Start: 769
• Page End: 772
• Publication Date: 2004-08-27
• Subjects: ASIC, acid sensing ion channel -- CPZ, capsazepine -- I-RTX, iodo-resiniferatoxin -- RAR, rapidly adapting receptor -- TRPV1, transient receptor potential vanilloid-1; cough -- guinea pig -- vanilloid receptor-1 (TRPV1) -- iodo-resiniferatoxin (I-RTX); Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thx.2003.012930
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Background: Iodo-resiniferatoxin (I-RTX) has recently been described as an ultra potent antagonist of the transient receptor potential vanilloid-1 (TRPV1). Methods: The ability of I-RTX to inhibit cough induced by inhalation of two putative TRPV1 stimulants (capsaicin and citric acid) was tested in non-anaesthetised guinea pigs. Results: Pretreatment with I-RTX either intraperitoneally (0.03–0.3 µmol/kg) or by aerosol (0.1–3 µM) reduced the number of coughs produced by inhalation of citric acid (0.25 M) and capsaicin (30 µM) in a dose dependent manner. Capsazepine (CPZ) also reduced citric acid and capsaicin induced cough, but the activity of I-RTX was 10–100 times more potent than CPZ in all the experimental conditions tested. Conclusions: I-RTX is a novel and potent antitussive drug which inhibits cough mediated by agents possibly acting via TRPV1 activation.